

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target

Feyza Gul Ozbay Kurt, ... , Jochen Utikal, Viktor Umansky

J Clin Invest. 2023;133(13):e170762. <https://doi.org/10.1172/JCI170762>.

Review

Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells that can suppress antitumor immune responses mediated by T and natural killer cells and promote tumor growth. They are major contributors to ICI resistance and play a crucial role in creating an immunosuppressive tumor microenvironment. Therefore, targeting MDSCs is considered a promising strategy to improve the therapeutic efficacy of ICIs. This Review describes the mechanism of MDSC-mediated immune suppression, preclinical and clinical studies on MDSC targeting, and potential strategies for inhibiting MDSC functions to improve melanoma immunotherapy.

Find the latest version:

<https://jci.me/170762/pdf>



Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target

Feyza Gul Ozbay Kurt,^{1,2,3,4} Samantha Lasser,^{1,2,3,4} Ihor Arkhypov,^{1,2,3,4} Jochen Utikal,^{1,2,3} and Viktor Umansky^{1,2,3,4}

¹Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany. ²Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, Germany. ³DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany. ⁴Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, Germany.

Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells that can suppress antitumor immune responses mediated by T and natural killer cells and promote tumor growth. They are major contributors to ICI resistance and play a crucial role in creating an immunosuppressive tumor microenvironment. Therefore, targeting MDSCs is considered a promising strategy to improve the therapeutic efficacy of ICIs. This Review describes the mechanism of MDSC-mediated immune suppression, preclinical and clinical studies on MDSC targeting, and potential strategies for inhibiting MDSC functions to improve melanoma immunotherapy.

Introduction

Melanoma accounts for the vast majority of skin cancer-related deaths. It is known for its high immunogenicity, which makes the disease a suitable target for immunotherapies (1) that deploy the patient's own immune system to fight against tumors (2). Earlier immunotherapeutic approaches involved the administration of cytokines and interferons, which displayed minimal benefit and considerable toxicities. The application of negative immune checkpoint molecules such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) as therapeutic targets has revolutionized cancer immunotherapy. Immune checkpoint inhibitors (ICIs) were first administered to patients with advanced melanoma and showed promising results (3). Yet many patients develop diverse resistance mechanisms that decrease the response rate to the treatment (4).

Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells with immunosuppressive functions and are known to be enriched in various types of cancer, including melanoma (5–7). The clinical relevance of MDSCs has gained attention owing to the reports showing that increased levels of MDSCs positively correlated with unfavorable clinical outcome and poor survival in different cancer entities (8, 9). Moreover, several reports highlighted a correlation between high MDSC numbers and poor response to ICI. This is attributed to the ability of MDSCs to foster an immunosuppressive tumor microenvironment, which hinders the efficacy of ICIs (10–12).

Current strategies aimed at targeting MDSCs are not entirely effective because of the heterogeneity of these myeloid cells and

the complexity of their immunosuppressive function (7). Therapies that included ICIs in combination with MDSC blockers showed potential, yet the absence of definitive markers to identify MDSCs poses a formidable challenge (13). Although several potential MDSC markers and novel factors involved in MDSC accumulation, immunosuppressive functions, and recruitment have been identified, their clinical utility remains to be elucidated.

In this Review, we present current knowledge on the role of MDSCs in the immunotherapy of melanoma. We describe the accumulation, infiltration, and immunosuppressive functions of MDSCs in the tumor microenvironment (TME) as well as existing therapeutic strategies to target them in melanoma-bearing hosts. A special focus is placed on preclinical studies and clinical trials applying MDSC inhibition to overcome resistance to ICIs. Recently identified novel markers for MDSC targeting in melanoma are also discussed.

Origin and phenotype of MDSCs

MDSCs are immature immunosuppressive myeloid cells or mature myeloid cells that acquired immunosuppressive functions (7, 14). These cells accumulate under chronic inflammatory conditions such as cancer, autoimmune diseases, and chronic infections (14). Under normal conditions, hematopoietic progenitor cells differentiate in the bone marrow into common myeloid progenitors that later give rise to immature myeloid cells, terminally differentiating into macrophages, dendritic cells (DCs), and granulocytes. Pathological conditions such as cancer lead to the dysregulated production of inflammatory signals and hematopoietic growth factors, which can initiate emergency myelopoiesis (15, 16). In this condition, the normal differentiation process of myeloid cells is impaired by the persistent production of growth factors and inflammation signals, resulting in the accumulation of immature myeloid cells (17). In contrast to normal counterparts, these immature myeloid cells, termed MDSCs, display weak phagocytic activity and antiinflammatory and immunosuppres-

Authorship note: JU and VU are co-senior authors.

Conflict of interest: The authors have declared that no conflict of interest exists.

Copyright: © 2023, Ozbay Kurt et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: *J Clin Invest.* 2023;133(13):e170762.

<https://doi.org/10.1172/JCI170762>.

sive functions, as well as immature phenotypes and morphologies (18). Further, it has been demonstrated that mature myeloid cells could be converted into MDSCs upon treatment with tumor-derived extracellular vesicles (EVs) (19–21). EVs are abundantly secreted by cancer cells and contain lipids, proteins, RNAs, and microRNAs (miRNAs) (22). It was demonstrated that miRNAs promoted MDSC generation, suppressive function, and expansion via targeting of transcription factors including suppressor of cytokine signaling (SOCS), CCAAT/enhancer binding protein (C/EBP), RUNX family transcription factor 1 (RUNX1), signal transducer and activator of transcription (STAT), and phosphatase and tensin homolog (PTEN) (23). EVs derived from human melanoma cells were shown to skew monocyte differentiation into immunosuppressive cells via a set of miRNAs (miRNA-146a, -155, -125b, -100, -125a, -146b, -99b, and let-7e) (21). It was also found that EVs secreted by mouse or human melanoma cells can convert normal monocytes into immunosuppressive MDSCs via programmed cell death protein ligand 1 (PD-L1) upregulation induced by HSP86/TLR4/NF- κ B signaling (20).

MDSCs are categorized into two major subsets, polymorphonuclear (PMN-MDSCs) and monocytic (M-MDSCs), based on their phenotypic and morphological resemblance to granulocytes and monocytes, respectively. In addition, a small subset of human myeloid cells comprising more immature progenitors are defined as early-stage MDSCs (e-MDSCs) (13). In mice, MDSCs are characterized as Gr1⁺ (Ly6G⁺ and Ly6C⁺) CD11b⁺ cells. In mice, PMN-MDSCs are defined as CD11b⁺Ly6G⁺Ly6C^{lo} and M-MDSCs as CD11b⁺Ly6G⁻Ly6C^{hi}. In humans, PMN-MDSCs express CD15, CD33, and CD11b, no CD14, and low or no HLA-DR expression, whereas M-MDSCs express CD14, CD33, and CD11b with a lack of CD15 and low or no HLA-DR expression. In addition, e-MDSCs are defined as HLA-DR⁺CD33⁺CD14⁻CD15⁻ cells (18). Human M-MDSCs could be distinguished from monocytes based on the level of HLA-DR expression. In contrast to neutrophils, which are purified on a higher density gradient, PMN-MDSCs are enriched in the low-density fraction after gradient centrifugation using the Ficoll gradient (18).

Additional markers including lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) have been used to distinguish human PMN-MDSCs from normal neutrophils (24). Moreover, CD84, a member of the signaling lymphocytic activation molecule (SLAM) family, and JAML, a member of the junctional adhesion molecule (JAM) family, have been demonstrated to be coexpressed on human MDSCs and to correlate with MDSC immunosuppressive activity in breast cancer (25). Despite the existence of MDSC markers and their phenotypic definition, the identification of MDSCs is still based on the assessment of their suppressive activity, since they share multiple genes with conventional neutrophils and monocytes (7).

Accumulation and recruitment of MDSCs

It has been reported that two partially overlapping signals are required for MDSC accumulation and activation (Figure 1) (7). Tumor cell-derived mediators such as stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), monocyte colony-stimulating factor (M-CSF), and vascular endothelial growth

factor (VEGF) make up the first group of signals that stimulate myelopoiesis and promote MDSC expansion (26). These mediators stimulate STAT and Janus kinase (JAK) proteins. Transcriptional factors or regulators involved in the accumulation of MDSCs include STAT3, STAT4, C/EBP- β , Notch, interferon regulatory factor 8 (IRF8), etc. (27). The second group of signals includes inflammatory cytokines produced mainly by host cells in the TME, such as IL-6, IL-4, IL-1 β , and prostaglandin E₂ (PGE₂). Other molecules, like Toll-like receptor (TLR) agonists and damage-associated molecular patterns, including high-mobility group box 1 (HMGB1), S100 calcium-binding proteins, tumor-derived heat shock proteins (HSPs), and complement component C5a, are reported to contribute to MDSC generation (14, 28). Long-term secretion of these mediators can promote the activation and immunosuppressive activity of MDSCs. Furthermore, NF- κ B, STAT1, and STAT6 transcription factors are also involved in this process (6). Secretion of a high level of cytokines including TGF- β , IL-1 β , IL-10, and TNF- α mediates the acquisition of MDSC immunosuppressive features (29). TNF- α was shown to induce the phosphorylation of STAT3, resulting in the differentiation of myeloid progenitor cells into MDSCs (29). Sinha et al. (30) demonstrated that STAT3 induced S100A8/9 proinflammatory proteins, which foster the accumulation of MDSCs. Moreover, inhibition of S100A8/9 has been shown in various mouse tumor models to restrain tumor growth by reducing MDSC accumulation (31–33).

MDSCs are recruited to the TME by chemokines derived from both tumor and stroma cells (Figure 1). It has been demonstrated that chemokines such as CXCL5, CXCL6, CXCL12, CXCL8, CXCL1, CCL2, CCL3, CCL4, and CCL5 play an important role in MDSC recruitment (34). However, these chemokines are also critical for the recruitment of conventional neutrophils and monocytes, indicating the problems associated with specific MDSC targeting (35). Additionally, TME-derived hypoxia is one of the crucial factors stimulating the recruitment of MDSCs (36–38). Hypoxia-inducible factor-1 α (HIF-1 α) was found to be involved in generating M2 macrophages from monocytes inside a tumor (39).

Several studies indicated that MDSC subsets and tumor entities could determine which chemokines support MDSC migration into the tumor site (40). CCR2 signaling was demonstrated to mediate M-MDSC recruitment, which promoted suppression of CD8⁺ T cell infiltration into the tumor site in melanoma patients (41). The CCR5 ligands CCL3, CCL4, and CCL5 were also reported to play roles in the migration of M-MDSCs (42). On the other hand, PMN-MDSCs are recruited primarily by CXC chemokines such as CXCL1, CXCL2, CXCL5, CXCL6, and CXCL12 produced by tumor cells (43, 44). PMN-MDSCs from melanoma-bearing mice were demonstrated to express CXCR2 (45), and CXCR2 deletion impaired PMN-MDSC accumulation, leading to tumor growth inhibition (45, 46).

Immunosuppressive functions

MDSCs use several mechanisms to suppress immune responses mediated by T, B, and natural killer (NK) cells, thus strongly accelerating tumor progression. The main mechanisms of T cell suppression are dealing with the expression of negative immune checkpoint molecules like PD-L1, depletion of amino acids required for T cell activation, production of reactive oxygen spe-




Figure 1. MDSC accumulation, recruitment, and functions in the TME. Inflammatory mediators released by host cells lead to the dysregulation of normal myelopoiesis and to the accumulation of MDSCs in the bone marrow. MDSCs expand and migrate to the TME through the interaction between CCR and CXCR and their corresponding chemokine ligands. In the TME, MDSCs are activated, and promote immunosuppression and tumor growth via various mechanisms. These mechanisms involve inhibiting the functions of T cells, NK cells, and DCs, promoting the differentiation of M2 macrophages, Tregs, and Bregs, and inducing angiogenesis and metastasis. Breg, regulatory B cell; CMP, common myeloid progenitor; HSC, hematopoietic stem cell.

cies (ROS) and nitric oxide (NO), and secretion of TGF- β and IL-10 (Figure 1) (29). MDSCs were shown to reduce the level of several amino acids essential for T cell functions (proliferation and cytokine production), such as cysteine, tryptophan, and L-arginine (47). The upregulation of arginase 1 (ARG1) and inducible NO synthase (iNOS) leads to the depletion of L-arginine amounts in the TME in different cancer entities (48, 49). Another important mechanism involved in MDSC immunosuppressive capacity is the activation of indoleamine 2,3-dioxygenase (IDO), an enzyme that converts L-tryptophan into *N*-formyl kynurenine (50, 51). The deficiency of L-tryptophan results in T cell anergy (51, 52).

A strong production of NO via iNOS activation and ROS by MDSCs was found to promote T cell anergy by the downregulation of T cell receptor ζ chain expression and even induce T cell apoptosis (53–55). Accumulated NO levels were shown to upregulate the expression of cyclooxygenase-2 (COX-2), leading to increased production of PGE₂ (56). The latter molecule was reported to promote the upregulation of immunosuppressive markers, including ARG1, IDO, and IL-10, in *in vitro*-generated MDSCs (57, 58).

It has been demonstrated that MDSCs express a high level of PD-L1, which interacts with PD-1 on T cells, inducing their anergy (37). Importantly, tumor-infiltrating MDSCs display higher PD-L1 expression than circulating MDSCs (59). Although some studies demonstrated that PD-L1 expression is predominantly restricted to M- and e-MDSCs (13), other publications described the presence of PD-L1 also on PMN-MDSCs (45, 60). MDSCs can also induce

the expansion of regulatory T cells (Tregs) through the secretion of TGF- β and IL-10 (61). Via the expression of the metalloprotease ADAM17, M-MDSCs are able to downregulate the expression of L-selectin (CD62L) on T cells, which impairs their extravasation and tissue infiltration capacity (62). Another mechanism used by MDSCs to suppress T cell function is the production of extracellular adenosine from ATP in the hypoxic TME via ectonucleotidases CD39 and CD73 (63, 64). Adenosine was found to impair the activation of T cells in cancer by inhibiting their proliferation and cytokine production (65).

Besides T cells, MDSCs can inhibit the function of other immune cells, such as NK cells, DCs, macrophages, and B cells. For instance, TGF- β produced by MDSCs was shown to promote the suppression of NK cell functions (66). Crosstalk between MDSCs and NK cells results in impaired NK cell cytotoxicity and induction of immune tolerance by reducing NKG2D expression and IFN- γ production (67). Moreover, PMN-MDSCs were reported to inhibit antigen cross-presentation by DCs in tumor-bearing mice (68). Furthermore, an accumulation of M-MDSCs in melanoma patients blocked DC maturation (6). MDSCs also hinder the function of B cells through the production of IL-7 and STAT5 signaling (69), and upregulate PD-L1 expression on B cells, thereby leading to the accumulation of regulatory B cells (70). Interaction between MDSCs and macrophages leads to the initiation of tumor-promoting immune response through upregulation of IL-10 production by MDSCs and downregulation of IL-12 secretion by macrophages (71).

Metabolic changes in MDSCs have been reported to be associated with the acquisition of their suppressive functions. It has been described that altered lipid metabolism in MDSCs plays a critical role in their differentiation and functions (72). In mice, polyunsaturated fatty acid-enriched diets were found to promote MDSC generation and to enhance MDSC suppressive activity (73). Al-Khami et al. (74) reported that tumor-infiltrating MDSCs increased fatty acid uptake and fatty acid oxidation to foster their immunosuppressive functions and found that intracellular accumulation of lipids in the TME enhanced the oxidative metabolism and activated immunosuppressive mechanisms of MDSCs in a mouse model of Lewis lung carcinoma. It has been recently reported that fatty acid transporter protein 2 (FATP2), responsible for the uptake of arachidonic acid and synthesis of PGE₂, is involved in the acquisition of PMN-MDSC suppressive activity (75). Inhibition of FATP2 was reported to abrogate PMN-MDSC functions and potentiate the efficacy of cancer immunotherapy in tumor-bearing mice (75). It was also demonstrated that MDSCs exhibit resistance to ferroptosis, a programmed cell death induced by iron-dependent lipid peroxidation (76). In a mouse model of colon cancer, tumor-infiltrating MDSCs were reported to overexpress a key ceramidase, *N*-acylsphingosine amidohydrolase 2 (*Asah2*), which protects MDSCs from ferroptosis. Correspondingly, in this study, inhibition of *Asah2* could reduce MDSC accumulation in colon tumors (77).

Furthermore, MDSCs can upregulate glycolytic pathways, which support their survival by preventing ROS-mediated apoptosis (78). M-MDSCs isolated from tumor tissue of patients with hepatocellular carcinoma displayed reduced cellular ATP content and failed to utilize glucose, which is mediated by the accumulation of methylglyoxal in MDSCs. By transferring methylglyoxal to T cells, MDSCs can suppress their function owing to the depletion of cytosolic amino acids such as L-arginine (79).

The TME is characterized by hypoxia, nutrient deprivation, acidic pH, and elevated levels of free radicals, which could stimulate the activation of ER stress sensors such as inositol-requiring enzyme-1 (IRE1), protein kinase RNA-like endoplasmic reticulum kinase (PERK), and activating transcription factor 6 (ATF6) that leads to the induction of ER stress in MDSCs (80). As a response to ER stress, the expression of C/EBP homologous protein (CHOP) is enhanced, resulting in the activation of proapoptotic genes. Enhanced CHOP expression in both human and mouse MDSCs contributed to their short lifespan and correlated with the ability of MDSCs to impair T cell responses (81).

In addition to their immunosuppressive function, MDSCs were shown to regulate tumor angiogenesis and vasculogenesis by producing high levels of matrix metalloproteinase 9 (MMP9) (82). Through STAT3 activation, MDSCs can also directly produce angiogenic factors like VEGF and basic fibroblast growth factor (bFGF) (83).

MDSCs in melanoma

Melanoma originates from the malignant transformation of melanocytes that can be found in different anatomic sites, including skin, conjunctiva, mucosal surfaces, and uveal structures (1, 84). Malignant melanoma is considered to be the most aggressive and fatal form of skin cancer. It results predominantly from oncogenic drivers, leading to constitutive activation of the MAPK path-

way, including mutations of BRAF (40%–50% of cases), NRAS (20%–30% of cases), and NF1 (10%–15% of cases) (85). Selective inhibitors of mutant BRAF (dabrafenib, encorafenib, or vemurafenib) are currently used in combination with MEK inhibitors (trametinib, binimetinib, or cobimetinib) for the treatment of metastatic melanoma (85). Compared with the earlier chemotherapeutic approaches, lower toxicity and increased overall survival have been achieved with BRAF inhibitor treatment (86). However, the treatment efficiency of MEK and BRAF inhibitors remains low since a significant number of patients acquire resistance (87). Studies reported that BRAF and MEK inhibitors could exert immunomodulatory effects (88). BRAF inhibition was reported to reduce the recruitment of MDSCs in the TME in melanoma-bearing mice (89). Furthermore, MEK inhibition was shown to prevent the polarization of monocytes into MDSCs and the infiltration of MDSCs into the TME in a mouse melanoma model (90). On the other hand, Steinberg et al. (91) reported that in mice with melanoma resistant to BRAF inhibitors, MDSC functions were restored after initial reduction, indicating the potential role of MDSCs in the acquisition of such resistance.

Melanoma has a high mutational burden and shows high immune infiltration, which makes it an ideal target for immunotherapy (92). Currently, approved immunotherapeutic regimens include nivolumab and pembrolizumab to target PD-1, ipilimumab to target CTLA-4, or a combination of antibodies against PD-1 and CTLA-4 (93). Administration of ICIs displayed initially a high response rate and improved clinical outcomes (94, 95). However, many patients develop various resistance mechanisms, which reduce the response rate to the treatment (4, 96). Resistance to ICIs primarily resulted in insufficient generation or dysfunction of antitumor effector T cells or inadequate formation of memory T cells (97). Since the TME was shown to determine the effectiveness of ICIs, tumor-infiltrating immune cells represent promising targets to improve the effect of ICIs (98). Melanoma cells produce various factors that induce the generation and enrichment of MDSCs, Tregs, cancer-associated fibroblasts, and tumor-associated macrophages (99, 100). Among these immunosuppressive cell populations, MDSCs are considered to play a major role in the immunosuppressive melanoma microenvironment (98, 99).

Chronic inflammation was reported to be associated with melanoma initiation and progression (101). Melanoma cells are able to produce various inflammatory mediators, such as GM-CSF, VEGF, TGF- β , TNF- α , IL-6, IL-1 β , IL-10, and chemokines (CCL2, CCL5, CXCL1, CXCL2, CXCL8, CXCL10). They can also induce the production of cytokines, chemokines, and growth factors by fibroblasts or immune cells, which can further stimulate the chemokine production by tumor cells, thereby creating autocrine and paracrine loops important for tumor progression (102). Long-term secretion of such inflammatory mediators induced MDSC accumulation and activation as well as the conversion of normal myeloid cells (like monocytes) into immunosuppressive MDSCs (102, 103).

Studies with *RET*-transgenic mice, which are characterized by the spontaneous development of skin malignant melanoma, revealed a profound accumulation of several inflammatory factors in melanoma lesions associated with MDSC enrichment in the melanoma microenvironment (104). These MDSCs strongly expressed ARG1 and PD-L1, produced high amounts of NOS and

Table 1. Clinical trials targeting MDSCs in melanoma

Title	Drug	Target	Strategy	Combination partner	Phase	Trial number
Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Stage IV Melanoma	ATRA	Retinoic acid receptor	Promotion of MDSC differentiation	Ipilimumab	II	NCT02403778
SX-682 Treatment in Subjects with Metastatic Melanoma Concurrently Treated with Pembrolizumab	SX-682	CXCR1/2	Blocking of MDSC recruitment	Pembrolizumab	I	NCT03161431
Combination Therapy with Nivolumab and PD-L1/IDO Peptide Vaccine to Patients with Metastatic Melanoma	I0102/I0103 peptide vaccine	IDO	Inhibition of MDSC suppressive functions	Nivolumab	I/II	NCT03047928
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549	IPI-549	PI3K	Inhibition of MDSC suppressive functions	Nivolumab	I	NCT02637531
A Study of Avelumab in Combination with Other Cancer Immunotherapies in Advanced Malignancies (JAVELIN Medley)	PD-0360324	CSF-1	Blocking of MDSC expansion	Avelumab	I/II	NCT02554812

ROS, and significantly inhibited T cell functions both in vitro and in vivo (104). Similar observations have been demonstrated in the peripheral blood of melanoma patients. Elevated numbers of M-MDSCs in advanced melanoma patients were found to be associated with a high level of inflammatory mediators such as IL-1 β and IFN- γ , which promotes MDSC accumulation and activation (105, 106). Other reports also showed an association between high levels of peripheral M-MDSCs and PMN-MDSCs and the tumor burden in patients with malignant melanoma (107, 108).

Several lines of evidence have illustrated the role of miRNAs in the expansion and activation of MDSCs (23). Huber et al. (21) reported that elevated expression of a set of miRNAs was significantly correlated with shorter progression-free survival in patients undergoing treatment with ipilimumab and nivolumab. Moreover, cancer stem cells could recruit MDSCs to regulate immunosuppression in the TME. For instance, downregulation of miRNA-92 expression in CD133⁺ melanoma stem cells potentiated the accumulation of MDSCs in the tumor site by enhancing integrin-dependent activation of TGF- β in melanoma-bearing mice (109).

Targeting MDSCs in melanoma therapy

A number of preclinical and clinical studies have been performed to evaluate the efficacy and safety of MDSC inhibition either as a single treatment or in combination with other therapies to improve antitumor responses and overcome the resistance of cancer cells (110–115). Ongoing clinical trials targeting MDSCs in melanoma patients are listed in Table 1. Current treatment strategies can be classified into five groups: (a) depletion of MDSCs; (b) inhibition of their suppressive functions; (c) blocking of their expansion and recruitment to the tumor site; (d) promotion of MDSC differentiation into mature myeloid cells; and (e) inhibition of MDSC metabolism (Figure 2) (35, 116).

MDSC depletion. Such chemotherapeutics as gemcitabine, 5-fluorouracil, paclitaxel, and doxorubicin were demonstrated to significantly reduce MDSC frequencies (116). Thus, low-dose paclitaxel could decrease the accumulation and immunosuppressive activity of tumor-infiltrating MDSCs in melanoma-bearing mice (117) and melanoma patients (118), leading to the inhibition of tumor progression. Moreover, the anti-CD33 monoclonal antibody gemtuzumab ozogamicin has recently been reported to deplete MDSCs, restore T cell immunity, and improve the efficiency of immunotherapy of various tumors, including melanoma (119). Furthermore, the

tyrosine kinase inhibitor sunitinib, which blocks several tyrosine kinases localized on both MDSCs and tumor cells, was reported to reduce MDSC frequencies via blockade of Fms-like tyrosine kinase 3 (Flt3), c-kit (CD117), and VEGF receptor (VEGFR) in patients with renal cell carcinoma (120, 121). Additionally, the TNF-related apoptosis-induced ligand receptor 2 (TRAIL-R2) agonistic antibody DS-8273a was demonstrated to eliminate MDSCs without affecting mature myeloid cells and to diminish the progression of disease among a cohort of patients with advanced malignancies (96). A phase I trial also tested the efficacy and safety of DS-8273a in combination with nivolumab in unresectable stage III/IV melanoma patients (ClinicalTrials.gov NCT02983006).

Inhibition of MDSC suppressive functions. Disruption of COX-2/PGE₂ pathway and phosphodiesterase-5 (PDE5) inhibitors such as sildenafil, vardenafil, and tadalafil has been employed to neutralize MDSC immunosuppressive capacities (35). Sildenafil was reported to reduce the expression of ARG1 and iNOS in MDSCs, and thereby inhibit their immunosuppressive functions (122). Furthermore, Meyer et al. (104) showed that sildenafil prolonged the survival of melanoma-bearing mice by reducing MDSC levels and activity, leading to restored CD8⁺ T cell infiltration and function in the TME. In an open-label trial with tadalafil, some metastatic melanoma patients resistant to ICI showed a response to the treatment that was associated with MDSC inhibition and accumulation of activated CD8⁺ T cells in metastatic lesions (123).

Blocking phosphatidylinositol 3-kinase (PI3K) was reported to reprogram MDSCs from an immunosuppressive to an immune-promoting phenotype (82). An ongoing phase I clinical trial with IPI-549, an inhibitor of PI3K, in combination with nivolumab is demonstrating improved clinical activity and safety in patients with stage III/IV melanoma who showed resistance to anti-PD-L1 therapy (NCT02637531).

Inhibiting IDO could be another strategy to block MDSC functions. Clinical trials in patients with advanced solid tumors using IDO inhibitors such as epacadostat (124), navoximod (NCT-02048709), EOS200271 (125), and BMS-986205 (NCT02658890) in combination therapies with ICIs showed that the treatment was effective and well tolerated. However, in a phase III trial, the combination of epacadostat with pembrolizumab in patients with unresectable or metastatic melanoma was not successful (NCT02752074). A preclinical study using an IDO vaccine to target IDO⁺ immunosuppressive cells in the TME demonstrated a depletion of immu-




Figure 2. Potential therapeutic approaches to target MDSCs. The main strategies to target MDSCs include MDSC depletion (A); inhibition of MDSC suppressive functions (B); blocking of MDSC expansion and recruitment (C); promotion of MDSC differentiation (D); and inhibition of MDSC metabolism (E). Relevant MDSC mechanisms are illustrated in each panel, and examples for each type of therapeutic approach are listed. AA, arachidonic acid; CMP, common myeloid progenitor; CPT1, carnitine palmitoyltransferase 1; FAO, fatty acid oxidation; FFAs, free fatty acids; GO, gemtuzumab ozogamicin; HSC, hematopoietic stem cell; TKIs, tyrosine kinase inhibitors; TSA, trichostatin A.

nosuppressive myeloid populations and improvement in antitumor effects in both IDO-expressing and non-IDO-expressing tumors from melanoma-bearing mice (114). Moreover, a phase I/II clinical trial in metastatic melanoma patients including an immunomodulatory vaccine (IO102/IO103) against IDO and PD-L1 showed a high response rate and improved progression-free survival (112).

STAT3 was found to be a promising target to diminish MDSC immunosuppressive functions (126). Diverse approaches targeting STAT3 inhibition have been evaluated in preclinical models and clinical trials (127–129). Nevertheless, clinical implementation in advanced solid tumors has yielded limited efficacy or intolerable

toxicities (130). We demonstrated previously that STAT3 inhibition by napabucasin reduced the immunosuppressive activity of MDSCs and prolonged the survival of melanoma-bearing mice (131). Moreover, STAT3 activation in circulating M-MDSCs from melanoma patients was found to be correlated with their poor progression-free survival, indicating the potential role of STAT3 as a predictive marker and a therapeutic target in melanoma (131).

The key cytokine IL-1 β , produced by inflammasome in response to damage-associated or pathogen-associated molecular patterns, was reported to be enriched in melanoma patients (132). Tengedal et al. (133) demonstrated that inhibition of tumor-derived

NLR family pyrin domain containing 3 (NLRP3) inflammasome by dapansutrile (OLT1177) in combination with ICIs reduced MDSC-mediated T cell suppression and thereby decreased tumor progression in melanoma-bearing mice.

Blocking MDSC expansion and recruitment. Growth factors such as SCF, GM-CSF, CSF, and VEGF are produced by tumor cells and could stimulate the expansion of MDSCs (134–136). Inhibiting MDSC development from the bone marrow progenitors by blocking SCF was reported to reduce MDSC expansion and tumor angiogenesis in a mouse model of colon cancer (137). Moreover, the blockade of GM-CSF/G-CSF signaling was reported to restrain the accumulation of MDSCs and reinvigorate antitumor immune responses (138). Furthermore, when combined with other therapies, CSF-1/CSF-1R blockade was also shown to inhibit MDSC expansion (139). A clinical trial with the CSF-1R inhibitor ARRY-382 in patients with advanced solid tumors including melanoma was terminated due to insufficient efficacy (NCT02880371). However, a phase I/II clinical trial to test the efficacy and safety of CSF-1R inhibitors (PD-0360324) in patients with melanoma is still ongoing (NCT02554812).

Blocking the interactions of chemokine receptors with their ligands to inhibit MDSC recruitment to the tumor site has been implicated as a therapeutic strategy. Anti-CXCR2 therapy was shown to reduce the accumulation of PMN-MDSCs in the TME, prolong survival, and decrease the occurrence of distant metastases in melanoma-bearing mice (45). Currently, SX-682, a CXCR1/2 inhibitor, is being tested in a phase I trial with pembrolizumab in patients with metastatic melanoma (NCT03161431).

Histone deacetylases (HDACs) and DNA methyltransferases can regulate antitumor immunity (140). HDAC inhibition has been shown to reduce MDSC recruitment to the tumor site, reinforce T cell activation, and thereby improve antitumor immune responses (141). The HDAC inhibitor entinostat applied in patients with metastatic uveal melanoma in combination with pembrolizumab was reported to promote durable antitumor responses (142). Moreover, Li et al. (143) reported that low-dose HDAC inhibitor trichostatin A in combination with anti-PD-L1 antibodies potentiated antitumor effects of immunotherapies and prolonged the survival of melanoma-bearing mice.

A number of reports demonstrated that MDSCs contribute to tumor growth by stimulating angiogenesis (83, 144, 145). In particular, MDSCs increase the proliferation and vasculogenic mimicry formation of melanoma cells (146). It has been demonstrated that the chemotherapeutic drug doxycycline remarkably reduced the ability of MDSCs to stimulate mimicry formation in melanoma cells, resulting in a strong antitumor effect when applied in combination with anti-PD-1 antibodies in melanoma-bearing mice (146). Moreover, anti-VEGF/VEGFR agents tested in clinical trials could reduce the recruitment of MDSCs and inhibit their angiogenesis-promoting effects in patients with metastatic non-small cell lung cancer (NSCLC) and colorectal cancer (147, 148). Additionally, a receptor for the proangiogenic factor angiopoietin 2, TIE-2, was reported to be expressed on circulating M-MDSCs from melanoma patients (149). TIE-2⁺ M-MDSCs overexpressed PD-L1, CD73, IL-10, and TGF- β and displayed high immunosuppressive activity against melanoma-specific T cells. The authors suggested that NGPT2/TIE-2 signaling represents a tumor escape

mechanism and that the combination of TIE-2 inhibitors and ICIs possesses therapeutic potential in melanoma (149).

Sun et al. (150) reported that the level of CXCL10 is greatly enhanced under tumor conditions and increased CXCL10 induces the accumulation of peripheral M-MDSCs, ultimately leading to tumor growth and metastasis in melanoma-bearing mice. This may indicate the importance of potential therapies targeting CXCL10 in the TME.

Artemisinin, an antimalarial drug, has been described as a promising therapeutic agent for cancer treatment (151). A preclinical study demonstrated that artemisinin therapy inhibited the accumulation and immunosuppressive activity of MDSCs, promoted antitumor T cell proliferation, and enhanced the efficacy of anti-PD-L1 therapy in melanoma-bearing mice (152).

Promotion of MDSC differentiation. All-*trans* retinoic acid (ATRA) was demonstrated to stimulate the maturation of myeloid cells into fully differentiated and less immunosuppressive variants (153). ATRA-induced differentiation of MDSCs into mature myeloid cells has been implicated in many preclinical and clinical studies (153, 154). In particular, a phase I/II clinical trial with a combination of ATRA and pembrolizumab revealed a favorable tolerability and high response rate in patients with stage IV melanoma (NCT02403778) (115).

Inhibition of MDSC metabolism. Another possibility to inhibit MDSC-mediated immunosuppression is to interrupt MDSC metabolism. In several tumor mouse models, the FATP2 inhibitor lipofermata alone or in combination with ICI blocked the activity of PMN-MDSCs and delayed tumor growth (75). Etomoxir is a small-molecule inhibitor of fatty acid oxidation (FAO), blocking carnitine palmitoyltransferase 1a (CPT1a), an important transporter critical for the oxidation of long-chain fatty acids in mitochondria (155). FAO inhibition by etomoxir was reported to decrease tumor growth in different mouse models by limiting MDSC fatty acid metabolism (156). Several studies demonstrated the association between the CD39/CD73/A2AR signaling pathway and poor cancer prognosis (64, 157, 158). An anti-CD73 antibody, oleclumab, is being tested together with anti-PD-L1 antibody (durvalumab) in various phase II trials in patients with NSCLC (NCT03822351, NCT03334617, NCT03794544). Moreover, clinical studies have also been performed to evaluate the safety and efficacy of the dual inhibition of adenosine receptors A2AR and A2BR (NCT05024097) or coinhibition of A2AR and CD73 (159) as a potential strategy to inhibit adenosine-mediated immunosuppression.

Itaconate, a tricarboxylic acid cycle-derived metabolite produced after the activation of immune response gene 1 (IRG1) by inflammatory stimuli, was found to be secreted by MDSCs (113, 160). Zhao et al. (160) demonstrated that itaconate derived from MDSCs suppressed CD8⁺ T cell proliferation and function. Furthermore, a loss of IRG1 diminished tumor growth and potentiated the efficacy of anti-PD-1 immunotherapy in the murine melanoma model, suggesting that IRG1 could be targeted to improve response to ICIs.

Novel markers for MDSC targeting in melanoma

Among potential novel surface markers for MDSC identification, another lipid transport receptor, CD36, was found to be upregulated in tumor-infiltrating PMN-MDSCs with increased immu-

nosuppressive functions in patients with renal cell carcinoma and colon adenocarcinoma (74). The deletion of CD36 or FAO inhibition resulted in decreased suppressive functions of MDSCs and increased efficacy of immunotherapy associated with delayed tumor growth in a mouse model of Lewis lung carcinoma (74).

General control nonderepressible 2 (GCN2), a serine-threonine kinase controlling transcription and translation in response to nutrient availability (161), was found to be a critical driver for the generation of tumor-associated macrophages and MDSCs in tumor-bearing hosts (162). Depletion of GCN2 decreased MDSC immunosuppressive functions and reduced IFN- γ expression in intratumoral CD8⁺ T cells in a mouse melanoma model (162). Increased GCN2 activity was also found to be correlated with a decreased overall survival in melanoma patients (162).

Another potential MDSC marker, immunoglobulin-like transcript 3 (ILT3), was found to play an important role in the acquisition of their immunosuppressive activity (163). MDSCs generated via melanoma cell lines were found to express high levels of ILT3, and ILT3 inhibition reduced the capacity of MDSCs to suppress T cells (164). Moreover, the ILT3^{hi} fraction of PMN-MDSCs were shown to be correlated with poor outcome in NSCLC patients (165), indicating that blocking of ILT3 may increase the antitumor responses by inhibiting MDSC functions.

Conclusion and future perspectives

ICI therapies have led to a significant improvement in the treatment of metastatic melanoma over the past decade. However, this improvement is not sufficient, and resistance develops over time due to a profound immunosuppression in the TME. MDSCs are strongly enriched in the melanoma microenvironment and employ several mechanisms to inhibit antitumor effector functions of T and NK cells (103). To enhance cancer immunotherapy, it is critically important to reprogram the unresponsive T cells in the TME to reinvigorate their antitumor functions (2). In this context, we have summarized the

current understanding of the mechanisms by which MDSCs could support the immunosuppressive melanoma microenvironment, as well as the current strategies that aim at MDSC inhibition to enhance antitumor immune responses and overcome the resistance to immunotherapy. A thorough understanding of the complex interactions between MDSCs and tumor cells as well as with other immune cells and the identification of novel surface markers that can distinguish MDSCs from normal myeloid cells are needed to develop more effective melanoma immunotherapies. However, some challenges exist in MDSC targeting. Blocking one single mechanism might not be sufficient to inhibit MDSC functions, since these cells are able to apply various suppression mechanisms simultaneously. Therefore, new studies are needed to find factors that could target more than one mechanism of suppression. Moreover, since MDSCs share multiple phenotypic similarities with their normal counterparts, many MDSC-targeting compounds suffer from a lack of specificity. Refinement of phenotypic definition is needed to modulate MDSCs without causing an impact on conventional monocytes and neutrophils. The use of high-dimensional single-cell technologies could be crucial for reducing the ambiguity by creating a precise definition of MDSCs, enabling functional manipulation, and ultimately incorporating MDSC targeting into clinical practice.

Acknowledgments

This work was supported by the German Academic Exchange Service (DAAD; to FGOK), the German Federal Ministry of Education and Research (BMBF)–SERPENTINE project in the ERA PerMed network (01KU2017 to VU), and the German Research Foundation (DFG), project 259332240/RTG 2099 (to JU and VU).

Address correspondence to: Viktor Umansky, Skin Cancer Unit, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Phone: 49.621.3833773; Email: v.umansky@dkfz.de.

- Schadendorf D, et al. Melanoma. *Lancet*. 2018;392(10151):971–984.
- Waldman AD, et al. A guide to cancer immunotherapy: from T cell basic science to clinical practice. *Nat Rev Immunol*. 2020;20(11):651–668.
- Wang DR, et al. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. *Signal Transduct Target Ther*. 2022;7(1):331.
- Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. *Nat Immunol*. 2022;23(5):660–670.
- Parker KH, et al. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. *Adv Cancer Res*. 2015;128:95–139.
- Umansky V, et al. The role of myeloid-derived suppressor cells (MDSC) in cancer progression. *Vaccines (Basel)*. 2016;4(4):36.
- Veglia F, et al. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. *Nat Rev Immunol*. 2021;21(8):485–498.
- Arihara F, et al. Increase in CD14⁺HLA-DR^{-/low} myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. *Cancer Immunol Immunother*. 2013;62(8):1421–1430.
- Huang A, et al. Increased CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. *Cancer Immunol Immunother*. 2013;62(9):1439–1451.
- Davis RJ, et al. Anti-PD-L1 efficacy can be enhanced by inhibition of myeloid-derived suppressor cells with a selective inhibitor of PI3K δ / γ . *Cancer Res*. 2017;77(10):2607–2619.
- Meyer C, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. *Cancer Immunol Immunother*. 2014;63(3):247–257.
- Tada K, et al. Pretreatment immune status correlates with progression-free survival in chemotherapy-treated metastatic colorectal cancer patients. *Cancer Immunol Res*. 2016;4(7):592–599.
- Cassetta L, et al. Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. *J Immunother*. 2020;8(2):e001223.
- Gabrilovich DI. Myeloid-derived suppressor cells. *Cancer Immunol Res*. 2017;5(1):3–8.
- Weiskopf K, et al. Myeloid cell origins, differentiation, and clinical implications. *Microbiol Spectr*. 2016;4(5):10.1128/microbiolspec.MCHD-0031-2016.
- Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. *J Clin Invest*. 2015;125(9):3356–3364.
- Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. *Cancer J*. 2010;16(4):348–353.
- Bronte V, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nat Commun*. 2016;7:12150.
- Valenti R, et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. *Cancer Res*. 2006;66(18):9290–9298.
- Fleming V, et al. Melanoma extracellular vesicles generate immunosuppressive myeloid cells by

- upregulating PD-L1 via TLR4 signaling. *Cancer Res.* 2019;79(18):4715–4728.
21. Huber V, et al. Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. *J Clin Invest.* 2018;128(12):5505–5516.
 22. Garcia-Martin R, et al. MicroRNA sequence codes for small extracellular vesicle release and cellular retention. *Nature.* 2022;601(7893):446–451.
 23. Daveri E, et al. MicroRNAs shape myeloid cell-mediated resistance to cancer immunotherapy. *Front Immunol.* 2020;11:1214.
 24. Condamine T, et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. *Sci Immunol.* 2016;1(2):aaf8943.
 25. Alshetaiwi H, et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. *Sci Immunol.* 2020;5(44):eaay6017.
 26. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. *Nat Rev Immunol.* 2009;9(3):162–174.
 27. Condamine T, et al. Transcriptional regulation of myeloid-derived suppressor cells. *J Leukoc Biol.* 2015;98(6):913–922.
 28. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. *Trends Immunol.* 2011;32(1):19–25.
 29. Groth C, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. *Br J Cancer.* 2019;120(1):16–25.
 30. Sinha P, et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. *J Immunol.* 2008;181(7):4666–4675.
 31. Cheng P, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. *J Exp Med.* 2008;205(10):2235–2249.
 32. Kinoshita R, et al. Newly developed anti-S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis. *Int J Cancer.* 2019;145(2):569–575.
 33. Qin H, et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. *Nat Med.* 2014;20(6):676–681.
 34. Kumar V, et al. The nature of myeloid-derived suppressor cells in the tumor microenvironment. *Trends Immunol.* 2016;37(3):208–220.
 35. Li K, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. *Signal Transduct Target Ther.* 2021;6(1):362.
 36. Chiu DK, et al. Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26. *Hepatology.* 2016;64(3):797–813.
 37. Noman MZ, et al. PD-L1 is a novel direct target of HIF-1 α , and its blockade under hypoxia enhanced MDSC-mediated T cell activation. *J Exp Med.* 2014;211(5):781–790.
 38. Chiu DK, et al. Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. *Nat Commun.* 2017;8(1):517.
 39. Kumar V, Gabrilovich DI. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. *Immunology.* 2014;143(4):512–519.
 40. De Cicco P, et al. The new era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion. *Front Immunol.* 2020;11:1680.
 41. Lesokhin AM, et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. *Cancer Res.* 2012;72(4):876–886.
 42. Blattner C, et al. CCR5⁺ myeloid-derived suppressor cells are enriched and activated in melanoma lesions. *Cancer Res.* 2018;78(1):157–167.
 43. Wang N, et al. Neutrophils infiltration in the tongue squamous cell carcinoma and its correlation with CEACAM1 expression on tumor cells. *PLoS One.* 2014;9(2):e89991.
 44. Kowalczyk O, et al. CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes. *Tumour Biol.* 2014;35(5):4619–4628.
 45. Groth C, et al. Blocking migration of polymorphonuclear myeloid-derived suppressor cells inhibits mouse melanoma progression. *Cancers (Basel).* 2021;13(4):726.
 46. Yang J, et al. Targeted deletion of CXCR2 in myeloid cells alters the tumor immune environment to improve antitumor immunity. *Cancer Immunol Res.* 2021;9(2):200–213.
 47. Cheng JN, et al. Myeloid-derived suppressor cells: a multifaceted accomplice in tumor progression. *Front Cell Dev Biol.* 2021;9:740827.
 48. Nagaraj S, et al. Altered recognition of antigen is a mechanism of CD8⁺ T cell tolerance in cancer. *Nat Med.* 2007;13(7):828–835.
 49. Rodriguez PC, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. *Cancer Res.* 2004;64(16):5839–5849.
 50. Yu J, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. *J Immunol.* 2013;190(7):3783–3797.
 51. Holmgaard RB, et al. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. *Cell Rep.* 2015;13(2):412–424.
 52. Munn DH. Blocking IDO activity to enhance anti-tumor immunity. *Front Biosci (Elite Ed).* 2012;4(2):734–745.
 53. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. *J Immunol.* 2009;182(8):4499–4506.
 54. Umansky V, Schirmacher V. Nitric oxide-induced apoptosis in tumor cells. *Adv Cancer Res.* 2001;82:107–131.
 55. Corzo CA, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. *J Immunol.* 2009;182(9):5693–5701.
 56. Obermajer N, Kalinski P. Key role of the positive feedback between PGE(2) and COX2 in the biology of myeloid-derived suppressor cells. *Oncoimmunology.* 2012;1(5):762–764.
 57. Obermajer N, Kalinski P. Generation of myeloid-derived suppressor cells using prostaglandin E2. *Transplant Res.* 2012;1(1):15.
 58. Lu C, et al. The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. *Oncoimmunology.* 2016;5(12):e1247135.
 59. Ostrand-Rosenberg S, et al. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. *J Immunol.* 2014;193(8):3835–3841.
 60. Patel A, et al. Multimodal intralesional therapy for reshaping the myeloid compartment of tumors resistant to anti-PD-L1 therapy via IRF8 expression. *J Immunol.* 2021;207(5):1298–1309.
 61. Siret C, et al. Deciphering the crosstalk between myeloid-derived suppressor cells and regulatory T cells in pancreatic ductal adenocarcinoma. *Front Immunol.* 2019;10:3070.
 62. Hanson EM, et al. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4⁺ and CD8⁺ T cells. *J Immunol.* 2009;183(2):937–944.
 63. Li J, et al. CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF- β -mTOR-HIF-1 signaling in patients with non-small cell lung cancer. *Oncoimmunology.* 2017;6(6):e1320011.
 64. Hatfield SM, Sitkovsky M. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1 α driven immunosuppression and improve immunotherapies of cancer. *Curr Opin Pharmacol.* 2016;29:90–96.
 65. Shevchenko I, et al. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses. *Oncoimmunology.* 2020;9(1):1744946.
 66. Mao Y, et al. Inhibition of tumor-derived prostaglandin-E2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. *Clin Cancer Res.* 2014;20(15):4096–4106.
 67. Tumino N, et al. Interaction between MDSC and NK cells in solid and hematological malignancies: impact on HSCT. *Front Immunol.* 2021;12:638841.
 68. Ugolini A, et al. Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer. *JCI Insight.* 2020;5(15):e138581.
 69. Wang Y, et al. Myeloid-derived suppressor cells impair B cell responses in lung cancer through IL-7 and STAT5. *J Immunol.* 2018;201(1):278–295.
 70. Liu M, et al. Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1(-)PD-L1(+) Bregs through PD-L1/PI3K/AKT/NF-kappaB axis in breast cancer. *Cell Death Dis.* 2021;12(5):465.
 71. Sinha P, et al. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. *J Immunol.* 2007;179(2):977–983.
 72. Siddiqui S, Glauben R. Fatty acid metabolism in myeloid-derived suppressor cells and tumor-associated macrophages: key factor in cancer immune evasion. *Cancers (Basel).* 2022;14(1):250.
 73. Yan D, et al. Polyunsaturated fatty acids promote the expansion of myeloid-derived suppressor cells by activating the JAK/STAT3 pathway. *Eur J*

- Immunol.* 2013;43(11):2943–2955.
74. Al-Khami AA, et al. Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. *Oncoimmunology.* 2017;6(10):e1344804.
 75. Veglia F, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. *Nature.* 2019;569(7754):73–78.
 76. Dang Q, et al. Ferroptosis: a double-edged sword mediating immune tolerance of cancer. *Cell Death Dis.* 2022;13(11):925.
 77. Zhu H, et al. Asah2 represses the p53-hmox1 axis to protect myeloid-derived suppressor cells from ferroptosis. *J Immunol.* 2021;206(6):1395–1404.
 78. Jian SL, et al. Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis. *Cell Death Dis.* 2017;8(5):e2779.
 79. Baumann T, et al. Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal. *Nat Immunol.* 2020;21(5):555–566.
 80. Lou X, et al. Endoplasmic reticulum stress mediates the myeloid-derived immune suppression associated with cancer and infectious disease. *J Transl Med.* 2023;21(1):1.
 81. Thevenot PT, et al. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. *Immunity.* 2014;41(3):389–401.
 82. Li X, et al. Targeting myeloid-derived suppressor cells to enhance the antitumor efficacy of immune checkpoint blockade therapy. *Front Immunol.* 2021;12:754196.
 83. Kujawski M, et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. *J Clin Invest.* 2008;118(10):3367–3377.
 84. Whiteman DC, et al. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. *Pigment Cell Melanoma Res.* 2011;24(5):879–897.
 85. Guo W, et al. Signal pathways of melanoma and targeted therapy. *Signal Transduct Target Ther.* 2021;6(1):424.
 86. Robert C, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. *N Engl J Med.* 2015;372(1):30–39.
 87. Tanda ET, et al. Current state of target treatment in braf mutated melanoma. *Front Mol Biosci.* 2020;7:154.
 88. Jung T, et al. Immunomodulatory properties of BRAF and MEK inhibitors used for melanoma therapy—paradoxical ERK activation and beyond. *Int J Mol Sci.* 2021;22(18):9890.
 89. Ho PC, et al. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFN γ . *Cancer Res.* 2014;74(12):3205–3217.
 90. Baumann D, et al. Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy. *Nat Commun.* 2020;11(1):2176.
 91. Steinberg SM, et al. Myeloid cells that impair immunotherapy are restored in melanomas with acquired resistance to BRAF inhibitors. *Cancer Res.* 2017;77(7):1599–1610.
 92. Marzagalli M, et al. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. *Semin Cancer Biol.* 2019;59:236–250.
 93. Eggermont AMM, et al. Combination immunotherapy development in melanoma. *Am Soc Clin Oncol Educ Book.* 2018;38:197–207.
 94. Hamid O, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. *Ann Oncol.* 2019;30(4):582–588.
 95. Larkin J, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med.* 2019;381(16):1535–1546.
 96. Johnson DB, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. *Nat Rev Clin Oncol.* 2022;19(4):254–267.
 97. Jenkins RW, et al. Mechanisms of resistance to immune checkpoint inhibitors. *Br J Cancer.* 2018;118(1):9–16.
 98. Petrova V, et al. Modern aspects of immunotherapy with checkpoint inhibitors in melanoma. *Int J Mol Sci.* 2020;21(7):2367.
 99. Navarini-Meury AA, Conrad C. Melanoma and innate immunity—active inflammation or just erroneous attraction? Melanoma as the source of leukocyte-attracting chemokines. *Semin Cancer Biol.* 2009;19(2):84–91.
 100. Falcone I, et al. Tumor microenvironment: implications in melanoma resistance to targeted therapy and immunotherapy. *Cancers (Basel).* 2020;12(10):2870.
 101. Kanterman J, et al. New insights into chronic inflammation-induced immunosuppression. *Semin Cancer Biol.* 2012;22(4):307–318.
 102. Zhao H, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. *Signal Transduct Target Ther.* 2021;6(1):263.
 103. Umansky V, et al. Myeloid-derived suppressor cells in malignant melanoma. *J Dtsch Dermatol Ges.* 2014;12(11):1021–1027.
 104. Meyer C, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. *Proc Natl Acad Sci U S A.* 2011;108(41):17111–17116.
 105. Jiang H, et al. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. *Int J Cancer.* 2015;136(10):2352–2360.
 106. Umansky V, et al. Predictive immune markers in advanced melanoma patients treated with ipilimumab. *Oncoimmunology.* 2016;5(6):e1158901.
 107. Weide B, et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. *Clin Cancer Res.* 2014;20(6):1601–1609.
 108. Schilling B, et al. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. *Int J Cancer.* 2013;133(7):1653–1663.
 109. Shidal C, et al. MicroRNA-92 expression in CD133⁺ melanoma stem cells regulates immunosuppression in the tumor microenvironment via integrin-dependent activation of TGF β . *Cancer Res.* 2019;79(14):3622–3635.
 110. Cheng P, et al. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma. *Mol Ther.* 2022;30(6):2315–2326.
 111. Gordy JT, et al. IFN α and 5-aza-2'-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model. *Front Immunol.* 2022;13:1074644.
 112. Kjeldsen JW, et al. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. *Nat Med.* 2021;27(12):2212–2223.
 113. Mills EL, et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. *Nature.* 2018;556(7699):113–117.
 114. Nandre R, et al. IDO vaccine ablates immune-suppressive myeloid populations and enhances antitumor effects independent of tumor cell IDO status. *Cancer Immunol Res.* 2022;10(5):571–580.
 115. Tobin RP, et al. Targeting MDSC differentiation using ATRA: a Phase I/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma. *Clin Cancer Res.* 2022;7(12):1209–1219.
 116. Fleming V, et al. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. *Front Immunol.* 2018;9:398.
 117. Sevko A, et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. *J Immunol.* 2013;190(5):2464–2471.
 118. Gebhardt C, et al. Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: a pilot study. *Cell Immunol.* 2021;360:104274.
 119. Fultang L, et al. MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers. *EBioMedicine.* 2019;47:235–246.
 120. Ko JS, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. *Clin Cancer Res.* 2009;15(6):2148–2157.
 121. Kodera Y, et al. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. *Breast Cancer Res.* 2011;13(3):R66.
 122. Serafini P, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. *J Exp Med.* 2006;203(12):2691–2702.
 123. Hassel JC, et al. Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe). *Oncoimmunology.* 2017;6(9):e1326440.
 124. Long GV, et al. Epcadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. *Lancet Oncol.* 2019;20(8):1083–1097.
 125. Gomes B, et al. Characterization of the selective indoleamine 2,3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(L)1 blockade therapy. *Mol Cancer Ther.* 2018;17(12):2530–2542.

126. Pinton L, et al. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. *Oncotarget*. 2016;7(2):1168–1184.
127. Xin H, et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. *Cancer Res*. 2009;69(6):2506–2513.
128. Liu F, et al. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. *J Invest Dermatol*. 2013;133(8):2041–2049.
129. Hong D, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. *Sci Transl Med*. 2015;7(314):314ra185.
130. Wong ALA, et al. Do STAT3 inhibitors have potential in the future for cancer therapy? *Expert Opin Investig Drugs*. 2017;26(8):883–887.
131. Bitsch R, et al. STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. *J Immunother Cancer*. 2022;10(3):e004384.
132. Karan D. Inflammasomes: emerging central players in cancer immunology and immunotherapy. *Front Immunol*. 2018;9:3028.
133. Tengesdal IW, et al. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. *Proc Natl Acad Sci U S A*. 2021;118(10):e2000915118.
134. Gabrilovich D, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. *Blood*. 1998;92(11):4150–4166.
135. Melani C, et al. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. *Blood*. 2003;102(6):2138–2145.
136. Wright MA, et al. Stimulation of immune suppressive CD34+ cells from normal bone marrow by Lewis lung carcinoma tumors. *Cancer Immunol Immunother*. 1998;46(5):253–260.
137. Pan PY, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. *Blood*. 2008;111(1):219–228.
138. Gargett T, et al. GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells in vitro. *Clin Transl Immunology*. 2016;5(12):e119.
139. Gomez-Roca CA, et al. Phase I study of ematuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. *Ann Oncol*. 2019;30(8):1381–1392.
140. Verza FA, et al. Roles of histone deacetylases and inhibitors in anticancer therapy. *Cancers (Basel)*. 2020;12(6):1664.
141. Li G, et al. The roles of histone deacetylases and their inhibitors in cancer therapy. *Front Cell Dev Biol*. 2020;8:576946.
142. Ny L, et al. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. *Nat Commun*. 2021;12(1):5155.
143. Li X, et al. HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. *Oncogene*. 2021;40(10):1836–1850.
144. Kowanetz M, et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. *Proc Natl Acad Sci U S A*. 2010;107(50):21248–21255.
145. Priceman SJ, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. *Blood*. 2010;115(7):1461–1471.
146. Li Y, et al. Targeting myeloid-derived suppressor cells to attenuate vasculogenic mimicry and synergistically enhance the anti-tumor effect of PD-1 inhibitor. *iScience*. 2021;24(12):103392.
147. Martino EC, et al. Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. *Cell Death Discov*. 2016;2:16025.
148. Manzoni M, et al. Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. *Oncology*. 2010;79(3-4):187–196.
149. Marguier A, et al. TIE-2 signaling activation by angiopoietin 2 on myeloid-derived suppressor cells promotes melanoma-specific T-cell inhibition. *Front Immunol*. 2022;13:932298.
150. Sun Y, et al. CXC chemokine ligand-10 promotes the accumulation of monocyte-like myeloid-derived suppressor cells by activating p38 MAPK signaling under tumor conditions. *Cancer Sci*. 2023;114(1):142–151.
151. Xu C, et al. Artemisinins as anticancer drugs: novel therapeutic approaches, molecular mechanisms, and clinical trials. *Front Pharmacol*. 2020;11:529881.
152. Zhang M, et al. Targeting inhibition of accumulation and function of myeloid-derived suppressor cells by artemisinin via PI3K/AKT, mTOR, and MAPK pathways enhances anti-PD-L1 immunotherapy in melanoma and liver tumors. *J Immunol Res*. 2022;2022:2253436.
153. Mirza N, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. *Cancer Res*. 2006;66(18):9299–9307.
154. Kusmartsev S, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. *Cancer Res*. 2003;63(15):4441–4449.
155. O'Connor RS, et al. The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. *Sci Rep*. 2018;8(1):6289.
156. Hossain F, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. *Cancer Immunol Res*. 2015;3(11):1236–1247.
157. Xia C, et al. CD39/CD73/A2AR pathway and cancer immunotherapy. *Mol Cancer*. 2023;22(1):44.
158. Augustin RC, et al. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. *J Immunother Cancer*. 2022;10(2):e004089.
159. Young A, et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. *Cancer Cell*. 2016;30(3):391–403.
160. Zhao H, et al. Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growth. *Nat Metab*. 2022;4(12):1660–1673.
161. Harding HP, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. *Mol Cell*. 2000;6(5):1099–1108.
162. Halaby MJ, et al. GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment. *Sci Immunol*. 2019;4(42):eaax8189.
163. Paavola KJ, et al. The fibronectin-ILT3 interaction functions as a stromal checkpoint that suppresses myeloid cells. *Cancer Immunol Res*. 2021;9(11):1283–1297.
164. Singh L, et al. ILT3 (LILRB4) promotes the immunosuppressive function of tumor-educated human monocytic myeloid-derived suppressor cells. *Mol Cancer Res*. 2021;19(4):702–716.
165. de Goeje PL, et al. Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer. *Oncimmunology*. 2015;4(7):e1014242.